Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

ARROWHEAD PHARMACEUTICALS, INC. ARWR

· Materials · Pharmaceutical Preparations

FY2026 10-K, filed 2026-11-12
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 4/5 core metrics

Latest reported annual revenue changed -45.6% from the prior reported annual observation.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Revenue contracted

    Latest reported annual revenue changed -45.6% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2026-09-30.

  • Operating margin compressed

    Operating margin changed -168.7 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2026-09-30.

  • Free cash flow was negative

    Latest reported free cash flow was -$284M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2026-09-30.

  • 6 filing risk checks flagged

    Flagged areas: Earnings quality, Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Latest annual revenue growth
-45.6%
as of 2026-09-30
Latest annual operating margin
-156.9%
as of 2026-09-30
Free cash flow
-$284M
as of 2026-09-30
ROIC snapshot
-120.0%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

6of 9 rule-based checks flagged
  • Earnings quality
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-11-22
Latest period end
2026-09-30
Filings
EDGAR ↗

Reported segment mix

Not available for ARWR: no dimensional revenue or operating-income facts for this filer in the ingested DERA files (segment, product/service, geography axes). Missing is not zero - a filer that reports one segment simply has no split to show.

Peer percentiles

latest fiscal year ending 2026-09-30 · among 4,026 US-listed filers · 781 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$451M
42ndof 3,198
middle third
60thof 502
middle third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
-45.6%
3rdof 3,041
bottom third
9thof 456
bottom third
Operating margin
operating income ÷ revenue
-156.9%
14thof 2,733
bottom third
37thof 465
middle third
Net margin
net income ÷ revenue
-160.6%
13thof 3,157
bottom third
34thof 495
middle third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
-63.0%
14thof 2,598
bottom third
37thof 420
middle third
Return on equity
net income ÷ stockholders' equity (positive equity only)
-1439.4%
1stof 3,488
bottom third
1stof 684
bottom third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
15.1%
19thof 2,809
bottom third
41stof 456
middle third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
8 days
91stof 2,340
top third
93rdof 374
top third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-29.0%
92ndof 3,803
top third
88thof 742
top third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2026-09-30 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-29.0%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-
change in net operating assets ÷ average net operating assets
Cash-backed years
5 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
-
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 3 changed periods
Line itemPeriodFirst reportedLatest filingChangeFilings
Depreciation and amortization
DepreciationDepletionAndAmortization
quarter 2020-03-31$946K
10-Q 2020-05-07
$900K
10-Q 2021-05-04
-4.9%first · latest
Depreciation and amortization
DepreciationDepletionAndAmortization
quarter 2020-06-30$1.11M
10-Q 2020-08-05
$1.1M
10-Q 2021-08-05
-1.0%first · latest
Depreciation and amortization
DepreciationDepletionAndAmortization
fiscal year 2020-09-30$4.24M
10-K 2020-11-23
$4.2M
10-K 2022-11-28
-1.0%first · latest · 3 filings carry it

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding; share counts re-presented by an integer split ratio are listed as split adjustments, not restatements. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

debt, leases, revenue, segments, contingencies, taxes and more · the filer's own words
Latest annual report10-K FY2025 · filed 20251125View filing
Commitments and contingencies · 2,046 characters as filed

COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of September 30, 2025 and 2024. On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (Ionis) to declare that the United States Patent No. 9,593,333 (the 333 patent) is invalid and not infringed by the Companys planned commercialization of investigational plozasiran. On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the 333 patent by the Companys planned commercialization of investigational plozasiran and seeking damages. There were no contingent liabilities recorded related to this litigation. Commitments The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support the Companys manufacturing, process development, an …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Employee benefit plans · 964 characters as filed

EMPLOYEE BENEFIT PLANS The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. All of the Companys full-time employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participants first 3% of compensation contributed plus 50% of each participants next 2% of compensation contributed. For the years ended September 30, 2025, 2024, and 2023, the Company recorded expenses for the matching contributions under this plan of $3.9 million, $3.4 million and $2.2 million, respectively. The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees. …

CompensationAndEmployeeBenefitPlansTextBlock · excerpt; the full note is in the filing

Revenue disaggregation · 297 characters as filed

The following table provides a summary of revenue recognized: Year Ended September 30, 2025 2024 2023 (in thousands) GSK $ 2,645 $ 2,685 $ 29,657 Horizon 23,206 Takeda 866 162,516 Janssen 356 Amgen 25,000 Sarepta 696,803 Sanofi $ 130,000 $ $ Total $ 829,448 $ 3,551 $ 240,735 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

Share-based compensation · 8,010 characters as filed

STOCK-BASED COMPENSATION The Company has three plans that provide for equity-based compensation. Under the 2013 Incentive Plan (the 2013 Plan), 2,276,279 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of September 30, 2025. Under the 2021 Incentive Plan (the 2021 Plan), 8,000,000 shares (subject to certain adjustments) of the Companys common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Companys common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September 30, 2025, 6,231,559 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 2,378,770 shares, which includes 170,898 and 439,431 shares that were forfeited under the 2013 and 2021 Plans, respectively. Under the Companys Inducement Plan (the Inducement Plan), 8 …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

Fair value · 4,130 characters as filed

FAIR VALUE MEASUREMENTS The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Companys own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date. Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows: Level 1 Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs are other than quoted prices in active markets, which are based on the following: Quoted prices for similar assets or liabilities in active markets; Quoted prices for identical or similar assets or liabilities in non-active markets; or Either directly or indirectly observable inputs as of the reporting date. Level 3 Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation. In ce …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Income taxes · 8,903 characters as filed

"INCOME TAXES Income Tax Provision (Benefit) The components of the income (loss) before income tax expense and noncontrolling interest are as follows: Year Ended September 30, 2025 2024 2023 (in thousands) Domestic $ (42,573) $ (582,333) $ (194,639) Foreign 94,106 (30,127) (7,852) Total $ 51,533 $ (612,460) $ (202,491) Income tax provision (benefit) consisted of the following components: Year Ended September 30, 2025 2024 2023 (in thousands) Current: Federal $ 21,440 $ 148 $ 1,074 State (56) 375 1,710 Foreign 35 (3,290) Total current tax $ 21,419 $ (2,767) $ 2,784 Deferred: Federal $ $ $ State Foreign Total deferred tax $ $ $ Income tax provision $ 21,419 $ (2,767) $ 2,784 The following table presents a reconciliation of the tax expense based on the statutory rate to the Companys actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: September 30, 2025 2024 2023 U.S. federal statutory income tax 21.0 % 21.0 % 21.0 % State income taxes, net of federal tax benefit (3.1) % 2.6 % 0.4 % Tax credits (44.4) % 3.0 % 6.8 % Permanent and other items (37.9) % 2.5 % (4.6) % Non-deductible compensation 5.1 % (0.9) % (4.6) % Foreign-derived intangible income deduction (16.2) % % 1.2 % Other income 11.1 % % % Stock compensation 10.7 % (0.7) % (1.1) % Valuation allowance 95.4 % (27.0) % (20.5) % Effective income tax rate 41.7 % 0.5 % (1.4) % Deferred Income Taxes The following table presents the signifi …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

Leases · 4,135 characters as filed

LEASES Pasadena, California : The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April 30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September 30, 2025. San Diego, California : The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 & 11408 Sorrento Valley Owner, LLC, which lease expires on April 30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September 30, 2025. The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (ATIA) funded by the lessor. The Company received $30.8 million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances …

LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing

Long-term debt · 7,738 characters as filed

"FINANCING AGREEMENT On August 7, 2024 (the Closing Date), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the Lenders), and Sixth Street Lending Partners (Sixth Street), as the administrative agent and collateral agent for the Lenders (the Financing Agreement). The Financing Agreement establishes a senior secured term loan facility of $500.0 million (the Credit Facility), consisting of $400.0 million funded on the Closing Date and an additional $100.0 million available at the Companys option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August 7, 2031. The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries. The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under …

LongTermDebtTextBlock · excerpt; the full note is in the filing

New accounting pronouncements · 3,370 characters as filed

"Recent Accounting Pronouncements In January 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2024-03, Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, in November 2024, and ASU 2025-01, Clarifying the Effective Date . These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued Accounting Standard Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

Segment reporting · 3,485 characters as filed

SEGMENT INFORMATION We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. The Company's RNAi therapeutics are comprised of siRNAs that function upstream of conventional medicines by potently silencing messenger RNA (mRNA) that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. Consistent with our operational structure, our Chief Executive Officer (CEO), as the CODM, manages and allocates resources on a consolidated basis at the global corporate level. Our global research and development and technical operations and quality organizations are responsible for the discovery, development, and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region and therapeutic area. All of these activities are supported by corporate staff functions. Managing and allocating resources at the corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources in line with our overarching long-term, corporate-wide strategic goals. The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the CODM for the purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Consistent with our management repor …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Stockholders' equity · 5,040 characters as filed

STOCKHOLDERS EQUITY The following table summarizes the Companys shares of common stock and preferred stock: Shares Par Value Authorized Issued Outstanding (in thousands) As of September 30, 2025 Common stock (1) $ 0.001 290,000 135,702 135,702 Preferred stock $ 0.001 5,000 As of September 30, 2024 Common stock $ 0.001 290,000 124,376 124,376 Preferred stock $ 0.001 5,000 (1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. As of September 30, 2025 and 2024, respectively, 9,851,400 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Companys 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. On November 25, 2024, the Company entered into a Securities Purchase Agreement (the Securities Purchase Agreement) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (Avoro Pre-Funded Warrants). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

Subsequent events · 2,387 characters as filed

SUBSEQUENT EVENTS Novartis On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the Novartis Collaboration Agreement) with Novartis Pharma AG (Novartis) for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases. Under the Novartis Collaboration Agreement, Novartis has received an exclusive worldwide license to the Company's ARO-SNCA preclinical stage program. The Novartis Collaboration Agreement closed on October 17, 2025 subsequent to clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Under the terms of the Novartis Collaboration Agreement, the Company received $200.0 million as an upfront payment. The Company is also eligible to receive $30.0 million associated with certain target nominations. Further, for each of the 4 programs, the Company is eligible to receive development milestone payments between $175.0 million and $245.0 million per program and sales milestone payments between $285.0 million and $370.0 million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits. Sarepta DM1 Milestone On November 20, 2025, the Company earned a $200.0 million milestone payment from Sarepta. The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNAi therapeutic for the treatment of type 1 m …

SubsequentEventsTextBlock · excerpt; the full note is in the filing

Latest quarterly report10-Q FY2026 Q1 · filed 20260205View filing
Commitments and contingencies · 2,118 characters as filed

COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of December 31, 2025. On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (Ionis) to declare that the United States Patent No. 9,593,333 (the 333 patent) is invalid and not infringed by the Companys planned commercialization of investigational plozasiran. On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the 333 patent by the Companys planned commercialization of investigational plozasiran and seeking damages. On December 23, 2025, the court granted Ionis motion to dismiss. The Company disputes the allegations of wrongdoing and intends to vigorously defend itself. Commitments The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and offic …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Revenue disaggregation · 253 characters as filed

The following table provides a summary of revenue recognized from our collaboration and license agreements: Three Months Ended December 31, 2025 2024 (in thousands) GSK $ $ 2,500 Sarepta 229,464 Novartis 34,242 Sanofi 209 Total $ 263,916 $ 2,500 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

Share-based compensation · 6,907 characters as filed

STOCK-BASED COMPENSATION The Company has three plans that provide for equity-based compensation. Under the 2013 Incentive Plan (the 2013 Plan), 1,721,592 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of December 31, 2025. Under the 2021 Incentive Plan (the 2021 Plan), 8,000,000 shares (subject to certain adjustments) of the Companys common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Companys common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of December 31, 2025, 6,789,307 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 1,833,483 shares, which includes 170,898 and 451,892 shares that were forfeited under the 2013 and 2021 Plans, respectively. Under the Company s Inducement Plan (the Inducement Plan), 83 …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

Fair value · 2,742 characters as filed

FAIR VALUE MEASUREMENTS The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Companys valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, Item 15. Exhibits and Financial Statement Schedules of its Annual Report on Form 10-K for the fiscal year ended September 30, 2025. The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. As of December 31, 2025 and September 30, 2025, the Company did not have any financial assets or financial liabilities based on Level 3 measurements. The following tables present information about the Companys assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company: December 31, 2025 Level 1 Level 2 Level 3 Total (in thousands) Available-for-s …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Leases · 4,071 characters as filed

LEASES Pasadena, California : The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April 30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of December 31, 2025. San Diego, California : The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 & 11408 Sorrento Valley Owner, LLC, which lease expires on April 30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of December 31, 2025. The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (ATIA) funded by the lessor. The Company received $30.8 million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances an …

LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing

Long-term debt · 8,246 characters as filed

"FINANCING AGREEMENT On August 7, 2024 (the Closing Date), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the Lenders), and Sixth Street Lending Partners (Sixth Street), as the administrative agent and collateral agent for the Lenders (the Financing Agreement). The Financing Agreement establishes a senior secured term loan facility of $500.0 million (the Credit Facility), consisting of $400.0 million funded on the Closing Date and an additional $100.0 million available at the Companys option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August 7, 2031. The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries. The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under …

LongTermDebtTextBlock · excerpt; the full note is in the filing

New accounting pronouncements · 1,475 characters as filed

Recent Accounting Pronouncements In January 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2024-03, Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, in November 2024, and ASU 2025-01, Clarifying the Effective Date . These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

Related parties · 792 characters as filed

RELATED PARTY DISCLOSURE The Company through its consolidated variable interest entity, Visirna, entered into an Asset Transfer Agreement closing on January 15, 2026 (the Asset Transfer Agreement) with Bisirna Therapeutics, Inc. (Bisirna). See Note 16, Subsequent Events. Bisirna is considered a related party because the CEO of the consolidated variable interest entity, Visirna, is the owner of Bisirna. Under the Asset Transfer Agreement, Visirna has agreed to sell and transfer certain assets and rights associated with R&D technology to Bisirna, subject to the satisfaction of closing conditions. As of December 31, 2025, the transaction has not closed and the Company has not recorded any amounts related to the transaction in the accompanying consolidated financial statements. …

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

Segment reporting · 3,374 characters as filed

SEGMENT INFORMATION We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. The Company's RNAi therapeutics are comprised of siRNAs that function upstream of conventional medicines by potently silencing messenger RNA (mRNA) that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. Consistent with our operational structure, our Chief Executive Officer (CEO), as the CODM, manages and allocates resources on a consolidated basis at the global corporate level. Our global research and development and technical operations and quality organizations are responsible for the discovery, development, and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region and therapeutic area. All of these activities are supported by corporate staff functions. Managing and allocating resources at the corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources in line with our overarching long-term, corporate-wide strategic goals. The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the CODM for the purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Consistent with our management repor …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Stockholders' equity · 6,173 characters as filed

STOCKHOLDERS EQUITY The following table summarizes the Companys shares of common stock and preferred stock: Shares Par Value Authorized Issued Outstanding (in thousands) As of December 31, 2025 Common stock (1) $ 0.001 290,000 140,052 137,391 Preferred stock $ 0.001 5,000 As of September 30, 2025 Common stock $ 0.001 290,000 138,363 135,702 Preferred stock $ 0.001 5,000 (1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. As of December 31, 2025 and September 30, 2025, respectively, 8,857,038 and 9,851,400 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Companys 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. On November 25, 2024, the Company entered into a Securities Purchase Agreement (the Securities Purchase Agreement) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (Avoro Pre-Funded Warrants). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and d …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

Subsequent events · 4,162 characters as filed

SUBSEQUENT EVENTS Convertible Senior Notes, Common Stock and Pre-Funded Warrants On January 7, 2026, Arrowhead Pharmaceuticals entered into separate underwriting agreements for concurrent offerings of equity and convertible notes: first, with Jefferies and J.P. Morgan to sell 3,100,776 shares of common stock, $0.001 par value per share, at a public offering price of $64.50 per share, or alternatively in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,550,387 shares of common stock, at a public offering price of $64.499, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, the Company granted the equity underwriters a 30-day option to purchase up to an additional 456,116 shares of common stock, on the same terms and conditions, which the equity underwriters exercised in full on January 8, 2026. The net proceeds from this equity offering was approximately $216.6 million after deducting customary underwriting discounts and offering expenses. These securities were issued under the Companys automatic shelf registration statement, which closed on January 9, 2026. Also on January 7, 2026, Arrowhead agreed with J.P. Morgan and Jefferies to issue $625.0 million of 0.00% convertible senior notes due 2032, with an additional $75.0 million overallotment option exercised in full on January 8, 2026. The net proceeds from the convertible notes …

SubsequentEventsTextBlock · excerpt; the full note is in the filing

Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.